Compass Pathways announced positive 52-week Part C results from its Phase 3 COMP005 study for treatment-resistant depression, showing durable and long-lasting benefits from its psilocybin treatment, COMP360. The data reinforces the therapy's efficacy and safety profile, leading to an 11% jump in stock price and supporting the ongoing FDA New Drug Application submission.
Compass Pathways released promising 52-week data for its psilocybin treatment, COMP360, for treatment-resistant depression. The results demonstrate sustained efficacy and a favorable safety profile, with participants showing significant reductions in MADRS scores and high response/remission rates. This positive data is crucial for the company's ongoing FDA New Drug Application, which is expected to be completed in Q4, with a commercial launch targeted for H1 2027. For traders, this reinforces the long-term potential of CMPS and the psychedelic-assisted therapy market, offering a strong bullish signal in the short term due to the stock's immediate jump and continued positive sentiment.